Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5732120 | 0.99 | TLR7 (0.63) | TLR7ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL5731164 | 0.93 | TLR7 (0.55) | TLR7ADORA2AADORA2BADORA1 | |
| SCHEMBL10174942 | 0.88 | TLR7 (0.49) | TLR7ADORA2AADORA1 | |
| SCHEMBL6153574 | 0.87 | TLR7 (0.63) | TLR7ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL14983804 | 0.85 | TLR7 (0.48) | TLR7ADORA2AADORA2BADORA1 | |
| SCHEMBL7209551 | 0.85 | TLR7 (0.48) | TLR7ADORA2AADORA2BADORA1 | |
| SCHEMBL5730393 | 0.85 | TLR7 (0.55) | TLR7ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL23421512 | 0.84 | TLR7 (0.48) | TLR7ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL27538541 | 0.84 | TLR7 (0.53) | TLR7 | |
| SCHEMBL5731379 | 0.84 | TLR7 (0.45) | TLR7ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200390881-A1 | NANOCARRIERS POSSESSING COMPONENTS WITH DIFFERENT RATES OF RELEASE | SELECTA BIOSCIENCES, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20180256709-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | SELECTA BIOSCIENCES, INC. (US) | 2018-09-13 | — | — | US | disclosed |
| US-9884112-B2 | Immunomodulatory agent-polymeric compounds | SELECTA BIOSCIENCES, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150328300-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | SELECTA BIOSCIENCES, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-9006254-B2 | Immunomodulatory agent-polymeric compounds | SELECTA BIOSCIENCES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140242173-A1 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOMODULATORY AGENTS | SELECTA BIOSCIENCES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140193453-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | SELECTA BIOSCIENCES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140030344-A1 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOSTIMULATORY AGENTS | SELECTA BIOSCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2435092-A2 | NANOCARRIERS POSSESSING COMPONENTS WITH DIFFERENT RATES OF RELEASE | Selecta Biosciences, Inc. (US) | 2012-04-04 | — | — | EP | disclosed |
| EP-2435095-A2 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | Selecta Biosciences, Inc. (US) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010138193-A2 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOMODULATORY AGENTS | SELECTA BIOSCIENCES, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| EP-1043021-B1 | PURINE DERIVATIVES FOR THE TREATMENT OF ALLERGIC DISEASES AND SYSTEMIC LUPUS ERYTHEMATOSUS | DAINIPPON SUMITOMO PHARMA CO (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-1551832-A1 | 8-AZABICYCLO[3.2.1]OCTANE ETHER DERIVATIVES AND THEIR USE AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-07-13 | — | — | EP | disclosed |
| EP-0882727-B9 | NOVEL PURINE DERIVATIVES | SUMITOMO PHARMA (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-0882727-B1 | NOVEL PURINE DERIVATIVES | SUMITOMO PHARMA (JP) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004031185-A1 | 8-AZABICYCLO[3.2.1]OCTANE ETHER DERIVATIVES AND THEIR USE AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| US-6376501-B1 | INHIBITING OR REGULATING IMMUNE RESPONSE USING PURINE-DERIVED COMPOUND; NON-STEROIDAL COMPOUND | JAPAN ENERGY CORPORATION (JP) | 2002-04-23 | — | — | US | disclosed |
| EP-1043021-A1 | TYPE 2 HELPER T CELL-SELECTIVE IMMUNE RESPONSE SUPPRESSORS | Japan Energy Corporation (JP) | 2000-10-11 | — | — | EP | disclosed |
| US-6028076-A | FOR INDUCING .ALPHA.-INTERFERON IN A PATIENT HAVING HEPATITIS B OR C, BY ADMINISTERING PURINE DERIVATIVE | JAPAN ENERGY CORPORATION (JP) | 2000-02-22 | — | — | US | disclosed |
| EP-0882727-A1 | NOVEL PURINE DERIVATIVES | JAPAN ENERGY CORPORATION (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328300-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | CD47, TLR3, IL2 | TLR7 41/4885ADORA3 3227/4885ADORA2A 1537/4885 |
| US-20200390881-A1 | NANOCARRIERS POSSESSING COMPONENTS WITH DIFFERENT RATES OF RELEASE | CD47, MSR1, CD14 | TLR7 118/4885ADORA3 2823/4885ADORA2A 1230/4885 |
| US-20180256709-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | CD47, TLR3, IL2 | TLR7 41/4885ADORA3 3227/4885ADORA2A 1537/4885 |
| US-20140193453-A1 | IMMUNOMODULATORY AGENT-POLYMERIC COMPOUNDS | CD47, TLR3, IL2 | TLR7 41/4885ADORA3 3227/4885ADORA2A 1537/4885 |
| US-20140030344-A1 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOSTIMULATORY AGENTS | CD47, IFNG, NFATC1 | TLR7 39/4885ADORA3 3439/4885ADORA2A 2179/4885 |
| US-20140242173-A1 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOMODULATORY AGENTS | CD47, IFNG, TSLP | TLR7 31/4885ADORA3 3217/4885ADORA2A 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.